Hansa Medical postpones the publishing of the annual report for the financial year of 2014

Hansa Medical AB (publ) has decided to postpone publishing its annual report for
the financial year of 2014 to April 29, 2015.
The annual report was previously scheduled to be published on March 23, 2015.

The reason for postponing the publishing of the annual report is the already
announced rescheduling of the Annual General Meeting to June 2, 2015.

About IdeS
IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that
cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and
efficiently. IdeS has been tested for safety and efficacy in numerous in vitro
and in vivo models. During 2013, a Phase I clinical trial on 29 healthy subjects
was conducted, demonstrating IdeS as efficacious and well tolerated with a
favorable safety profile. During 2014 and 2015, a Phase II clinical trial in
sensitized patients awaiting kidney transplantation has been conducted.
Preliminary data shows that IdeS has very good efficacy in highly sensitized
patients on the kidney transplant waitlist. The study shows that IdeS has the
capacity to make sensitized patients eligible for transplantation by decreasing
HLA antibodies to levels acceptable for transplantation. In addition to
transplantation, IdeS has potential indications within a variety of rare
autoimmune diseases including anti-GBM disease. IdeS is protected by several
patents and has been published in numerous peer review journals.

The information in this press release was released for public disclosure on
March 20, 2015 at 08.30 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CFO and acting CEO
Mobile: 46 706-33 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused
on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading
enzyme in clinical development, with potential use in transplantation and rare
autoimmune diseases. Other projects include HBP (a market introduced diagnostic
marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in
pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's
share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB
as Certified Adviser.